Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.59
CLVS's Cash to Debt is ranked lower than
74% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. CLVS: 1.59 )
Ranked among companies with meaningful Cash to Debt only.
CLVS' s Cash to Debt Range Over the Past 10 Years
Min: 0.91  Med: 10000.00 Max: No Debt
Current: 1.59
F-Score: 2
Z-Score: -2.40
M-Score: -4.19
WACC vs ROIC
11.10%
-422.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -133.27
CLVS's ROE (%) is ranked lower than
87% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. CLVS: -133.27 )
Ranked among companies with meaningful ROE (%) only.
CLVS' s ROE (%) Range Over the Past 10 Years
Min: -144.26  Med: -55.78 Max: -26.78
Current: -133.27
-144.26
-26.78
ROA (%) -51.57
CLVS's ROA (%) is ranked lower than
70% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. CLVS: -51.57 )
Ranked among companies with meaningful ROA (%) only.
CLVS' s ROA (%) Range Over the Past 10 Years
Min: -144.39  Med: -49.23 Max: -21.25
Current: -51.57
-144.39
-21.25
ROC (Joel Greenblatt) (%) -9948.89
CLVS's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. CLVS: -9948.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -9748.56  Med: -6584.15 Max: -3834.63
Current: -9948.89
-9748.56
-3834.63
EBITDA Growth (3Y)(%) 52.00
CLVS's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. CLVS: 52.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLVS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.9  Med: -13.50 Max: 52
Current: 52
-31.9
52
EPS Growth (3Y)(%) 48.90
CLVS's EPS Growth (3Y)(%) is ranked higher than
92% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CLVS: 48.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLVS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.1  Med: -12.60 Max: 48.9
Current: 48.9
-31.1
48.9
» CLVS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CLVS Guru Trades in Q2 2015

Steven Cohen 117,100 sh (unchged)
» More
Q3 2015

CLVS Guru Trades in Q3 2015

Paul Tudor Jones 4,131 sh (New)
Andreas Halvorsen 836,332 sh (New)
Jim Simons 128,900 sh (New)
Steven Cohen 117,100 sh (unchged)
» More
Q4 2015

CLVS Guru Trades in Q4 2015

Paul Tudor Jones 225,000 sh (+5346.62%)
Steven Cohen 117,100 sh (unchged)
Andreas Halvorsen Sold Out
Jim Simons Sold Out
» More
Q1 2016

CLVS Guru Trades in Q1 2016

Kyle Bass 100,000 sh (New)
Jim Simons 515,400 sh (New)
Steven Cohen 603,100 sh (unchged)
Paul Tudor Jones 13,858 sh (-93.84%)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:GBT, NAS:ADAP, NAS:NK, NAS:ARRY, NAS:RPTP, NAS:FLML, NAS:EPZM, NAS:XBIT, NAS:AMRI, OTCPK:PHMMF, NAS:PDLI, NAS:BPMC, NAS:DVAX, NAS:ZIOP, NAS:LOXO, NAS:AIMT, NAS:WVE, OTCPK:BIESF, NAS:VNDA, NAS:CLDX » details
Traded in other countries:C6O.Germany,
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.

Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.

Ratios

vs
industry
vs
history
P/B 2.31
CLVS's P/B is ranked higher than
65% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. CLVS: 2.31 )
Ranked among companies with meaningful P/B only.
CLVS' s P/B Range Over the Past 10 Years
Min: 1.28  Med: 4.16 Max: 11.72
Current: 2.31
1.28
11.72
EV-to-EBIT -0.92
CLVS's EV-to-EBIT is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. CLVS: -0.92 )
Ranked among companies with meaningful EV-to-EBIT only.
CLVS' s EV-to-EBIT Range Over the Past 10 Years
Min: -26  Med: -11.60 Max: -0.93
Current: -0.92
-26
-0.93
EV-to-EBITDA -0.93
CLVS's EV-to-EBITDA is ranked lower than
99.99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. CLVS: -0.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27  Med: -11.90 Max: -0.94
Current: -0.93
-27
-0.94
Current Ratio 6.27
CLVS's Current Ratio is ranked higher than
60% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CLVS: 6.27 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 11.28 Max: 31.09
Current: 6.27
0.86
31.09
Quick Ratio 6.27
CLVS's Quick Ratio is ranked higher than
61% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. CLVS: 6.27 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 11.28 Max: 31.09
Current: 6.27
0.86
31.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.81
CLVS's Price/Net Cash is ranked lower than
80% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. CLVS: 15.81 )
Ranked among companies with meaningful Price/Net Cash only.
CLVS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.45  Med: 8.98 Max: 51.38
Current: 15.81
2.45
51.38
Price/Net Current Asset Value 10.23
CLVS's Price/Net Current Asset Value is ranked lower than
75% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. CLVS: 10.23 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLVS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.43  Med: 8.46 Max: 41.79
Current: 10.23
2.43
41.79
Price/Tangible Book 8.18
CLVS's Price/Tangible Book is ranked lower than
75% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CLVS: 8.18 )
Ranked among companies with meaningful Price/Tangible Book only.
CLVS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.39  Med: 10.97 Max: 396.95
Current: 8.18
2.39
396.95
Earnings Yield (Greenblatt) (%) -107.71
CLVS's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. CLVS: -107.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -164.27  Med: 0.00 Max: 0
Current: -107.71
-164.27
0

More Statistics

EPS (TTM) $ -10.01
Beta1.83
Short Percentage of Float24.81%
52-Week Range $11.57 - 116.75
Shares Outstanding (Mil)38.39
» More Articles for CLVS

Headlines

Articles On GuruFocus.com
Kyle Bass Purchases Stake in Clovis Oncology May 25 2016 
Kyle Bass Builds Bull Case for Clovis Oncology Nov 27 2015 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
VBI Vaccines (VBIV) and Clovis Oncology (CLVS) Momentum Indicators; Wynn Resorts (WYNN) Power Battle Apr 07 2015 

More From Other Websites
Coverage Initiated on Select Biotech Equities Jul 11 2016
Buyout target Medivation says cancer drug could be 'best in class' Jul 06 2016
Clovis Oncology (CLVS) Jumps: Stock Adds 21.9% in Session Jun 30 2016
16 Biopharma Companies Besides Medivation That Are Attractive Targets Jun 29 2016
Here’s Why These Five Stocks Are On the Move on Wednesday Jun 29 2016
These 15 Biotech Companies Could Be Takeover Targets Jun 29 2016
CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 10 2016
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and... Jun 06 2016
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and... Jun 06 2016
Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and... Jun 06 2016
Redmile Group Sticking With Healthcare Picks After Rough Q1 Jun 03 2016
Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 Jun 01 2016
Trade sees ceiling in Clovis Oncology Jun 01 2016
Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting May 19 2016
Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting May 19 2016
Markets Are Defensive: XBI Outperforms the Market May 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)